Treatment of human papillomavirus infection in HIV-infected patients

Cover Page

Cite item

Abstract

The first reports about HIV (human immunodeficiency virus) were appeared to the 1980s. By 2017 more than 37 million people were living with HIV. Human papilloma virus (HPV) is universally spread, with some estimates showing that about 1% of the sexually active population having genital warts. Human papilloma virus (HPV)-induced infection frequently accompanies the clinical course of HIV and can manifest itself in a full spectrum of clinical-pathologic forms ranging from common warts to malignant neoplasia. Due to the widespread use of antiretroviral therapy, the number of patients with a combined infection (HIV+HPV) is steadily increasing. Here we review current clinical treatment options for HPV manifestations. High-dose antiretroviral therapy does not impede HPV treatment, and can even improve its efficacy in some cases. The topical administration of imiquimod, an immune response modifier, is an effective conservative treatment in HIV-infected patients with HPV. The immunomodulation therapy of imiquimod can serve as an effective alternative of aggressive chemical and mechanical procedures. Maximum efficacy with the lowest replaces rates may be expected from combined use of mechanical ablation methods with a subsequent follow up treatment with imiqui-mod. The best therapeutic result is expected in HIV-positive patients who are received high-dose antiretroviral treatment. The advantages of Vartocid, the modified Russian equivalent of the generic imiquimod.

About the authors

V. S. Smirnov

St. Petersburg Pasteur Institute; JSC MBSPC Cytomed

Author for correspondence.
Email: vssmi@mail.ru
ORCID iD: 0000-0002-2723-1496
http://cytomed.ru

Vyacheslav S. Smirnov - PhD, MD (Medicine), Professor, Leading Researcher, Laboratory Molecular Immunology, St. Petersburg PI; Head Researcher, JSC MBSPC Cytomed.

197101, St. Petersburg, Mira str., 14; Phone: +7 911 948-59-22 (mobile)

Russian Federation

T. A. Kudryavtseva

JSC MBSPC Cytomed

Email: tatjana_ku@inbox.ru
http://cytomed.ru

PhD (Biology), Leading Researcher, Scientific Department.

St. Petersburg

Russian Federation

References

  1. Покровский В.В. Синдром приобретенного иммунодефицита в России // Терапевтический архив. 2016, Т. 88, № 11. С. 4—11. doi: 10.17116/terarkh201688114-11
  2. Смирнов В.С., Кудрявцева Т.А. Вартоцид (Имихимод). СПб.: Гиппократ, 2017. 141 c.
  3. Федеральный научно-методический Центр по профилактике и борьбе со СПИДом. ВИЧ-инфекция в Российской Федерации на 30 сентября 2020 г. URL: http://www.hivrussia.info/wp-content/uploads/2020/11/Spravka-VICH-v-Rossii-9-mes-2020.pdf (27.11.2020)
  4. Cardoso J.C., Calonje E. Cutaneous manifestation of human papillomaviruses: a review. Acta Dermatovenerol. Alp. Panonica. Adriat., 2011, vol. 20, no. 3, pp. 145—154.
  5. Fox P.A., Nathan M., Francis N., Singh N., Weir J., Dixon G., Barton S.E., Bower M.A. Double-blind, randomized controlled trial of the use of imiquimod cream for the treatment of anal canal high-grade anal intraepithelial neoplasia in HIV-positive MSM on HAART, with long-term follow-up data including the use of open-label imiquimod. AIDS, 2010, vol. 24, no. 15, pp. 2331— 2335. doi: 10.1097/QAD.0b013e32833d466c
  6. Garland S.M. Imiquimod. Curr. Opin. Infect. Dis., 2003, vol. 16, no. 2, pp. 151—160.
  7. Godfrey J.C., Vaughan M.C., Williams J.V. Successful treatment of bowenoid papulosis in a 9-year-old girl with vertical acquired human immunodeficiency virus. Pediatrics, 2003, vol.112, no. 1, pp. e73-e76. doi: 10.1542/peds.112.1.e73
  8. Goldstone S., Palefsky J.M., Giuliano A.R. Prevalence of and risk factors for human papillomavirus (HPV) infection among HIV-seronegative men who have sex with men. J. Infect. Dis., 2011, vol. 203, no. 1, pp. 66—74. doi: 10.1093/infdis/jiq016.
  9. Gormley R.H., Kovarik C.L. Dermatologic manifestations of HPV in HIV-infected individuals. Curr. HIV/AIDS Rep., 2009, vol. 6, no. 3,pp. 130-138. doi: 10.1007/s11904-009-0018-8
  10. Gupta A.K., Browne M., Bluhm R. Imiquimod: a review. J. Cutan. Med. Surg., 2002, vol. 6, no. 6, pp. 554-560. doi: 10.1007/s10227-001-0134-6
  11. Hampson L., Martin-Hirsch P., Hampson I.N. An overview of early investigational drugs for the treatment of human papilloma virus infection and associated dysplasia. Expert Opin. Investig. Drugs., 2015, vol. 24, no. 12, pp. 1529-1537. doi: 10.1517/13543784.2015.1099628
  12. Hemelaar J., Elangovan R., Yun J., Dickson-Tetteh L., Fleminger I., Kirtley S., Williams B., Gouws-Williams E., Ghys P.D.; WHO-UNAIDS Network for HIV Isolation Characterisation. Global and regional molecular epidemiology of HIV-1, 1990— 2015: a systematic review, global survey, and trend analysis. Lancet Infect. Dis., 2019, vol. 19, no. 2, pp. 143-155. doi: 10.1016/S1473-3099(18)30647-9
  13. Hengge U.R., Benninghoff B., Ruzicka T., Gross M. Topical immunomodulators — progress towards treating inflammation, infection, and cancer. Lancet Infect. Dis., 2001, vol. 1, no. 3, pp. 189-198.
  14. Hengge U.R., Ruzicka T. Topical immunomodulation on in dermatology potential of toll-like receptor agonists. Dermatol. Surg., 2004, vol. 30, no. 8, pp. 1101-1112.
  15. Hidalgo-Tenorio C., de Jesus S.E., Esquivias J., Pasquau J. High prevalence and incidence of HPV-related anal cancer precursor lesions in HIV-positive women in the late HAART era. Enferm. Infecc. Microbiol. Clin., 2018, vol. 36, no. 9, pp. 555-562. doi: 10.1016/j.eimc.2017.10.014
  16. Kreuter A., Potthoff A., Brockmeyer N.H., Gambichler T., Stacker M., Altmeyer P., Swoboda J., Pfister H., Wieland U.; German Competence Network HIV/AIDS. Imiquimod leads to a decrease of human papillomavirus DNA and to a sustained clearance of anal intraepithelial neoplasia in HIV-infected men. J. Invest. Dermatol., 2008, vol. 128, no. 8, pp. 2078-2083. doi: 10.1038/jid.2008.24
  17. Krishnamurti U., Unger E.R. Pathobiology of human papillomaviruses in human immunodeficiency virus — infected persons. Semin. Diagn. Pathol., 2017, vol. 34, no. 4,pp. 364-370. doi: 10.1053/j.semdp.2017.04.005.
  18. Lim J.H.-L., Lim K.-S., Chong W.-S. Dramatic clearance of HIV-associated bowenoid papulosis using combined oral acitretin and topical 5% Imiquimod. J. Drugs Dermatol., 2014, vol. 13, no. 8, pp. 901-902.
  19. Lucas S., Nelson A.M. HIV and the spectrum of human disease. J. Pathol., 2015, vol. 235, no. 2, pp. 229-241. doi: 10.1002/path.4449.
  20. Mbulawa Z.Z., Marais D.J., Johnson L.F., Boulle A., Coetzee D., Williamson A.L. Influence of human immunodeficiency virus and CD4 count on the prevalence ofhuman papillomavirus in heterosexual couples. J. Gen. Virol., 2010, vol. 91, no. 12, pp. 30233031. doi: 10.1099/vir.0.020669-0.
  21. Miles to go — Global AIDS Update 2018. Geneva: UNAIDS, 2018. 268 p. URL: https://www.unaids.org/en/20180718_GR2018 (27.11.2020)
  22. Newsom-Davis T., Bower M. HIV-associated anal cancer. F1000 Med. Rep., 2010, vol. 2, no. 1: 85. doi: 10.3410/M2-85
  23. Obiri-Yeboah D., Akakpo P.K., Mutocheluh M., Adjei-Danso E., Allornuvor G., Amoako- Sakyi D., Adu-Sarkodie Y., Mayaud P. Epidemiology of cervical human papillomavirus (HPV) infection and squamous intraepithelial lesions (SIL) among a cohort of HIV-infected and uninfected Ghanaian women. BMC Cancer, 2017, vol. 17, no. 1: 688. doi: 10.1186/s12885-017-3682-x
  24. Redondo P., Lloret P. Topical imiquimod for bowenoid papulosis in an HIV-positive woman. Acta Derm. Venereol., 2002, vol. 82, no. 3, pp. 212-213. doi: 10.1080/00015550260132550
  25. Roberts J.R., Siekas L.L., Kaz A.M. Anal intraepithelial neoplasia: a review of diagnosis and management. World J. Gastrointest. Oncol., 2017, vol. 9, no. 2, pp. 50-61. doi: 10.4251/wjgo.v9.i2.50

Supplementary files

There are no supplementary files to display.


Copyright (c) 2021 Smirnov V.S., Kudryavtseva T.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies